These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23562004)

  • 1. Serum protein profile of Crohn's disease treated with infliximab.
    Gazouli M; Anagnostopoulos AK; Papadopoulou A; Vaiopoulou A; Papamichael K; Mantzaris G; Theodoropoulos GE; Anagnou NP; Tsangaris GT
    J Crohns Colitis; 2013 Nov; 7(10):e461-70. PubMed ID: 23562004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment.
    Magro F; Rodrigues-Pinto E; Santos-Antunes J; Vilas-Boas F; Lopes S; Nunes A; Camila-Dias C; Macedo G
    J Crohns Colitis; 2014 Feb; 8(2):129-36. PubMed ID: 23932786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
    Steenholdt C
    Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial.
    Yoshida K; Fukunaga K; Ikeuchi H; Kamikozuru K; Hida N; Ohda Y; Yokoyama Y; Iimuro M; Takeda N; Kato K; Kikuyama R; Nagase K; Hori K; Nakamura S; Miwa H; Matsumoto T
    Inflamm Bowel Dis; 2012 Sep; 18(9):1617-23. PubMed ID: 22081474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A; Straathof JW; Derijks LJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
    Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
    Mantzaris GJ; Viazis N; Petraki K; Papamichael K; Theodoropoulos I; Roussos A; Karakoidas C; Koilakou S; Raptis N; Smyrnidis A; Agalos G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1042-8. PubMed ID: 20139856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
    Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Fallingborg J; Christensen LA; Pedersen G; Kjeldsen J; Jacobsen BA; Oxholm AS; Kjellberg J; Bendtzen K; Ainsworth MA
    Gut; 2014 Jun; 63(6):919-27. PubMed ID: 23878167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant use of enteral nutrition therapy is associated with sustained response to infliximab in patients with Crohn's disease.
    Sazuka S; Katsuno T; Nakagawa T; Saito M; Saito K; Matsumura T; Arai M; Sato T; Yokosuka O
    Eur J Clin Nutr; 2012 Nov; 66(11):1219-23. PubMed ID: 23010687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
    Bortlik M; Duricova D; Malickova K; Machkova N; Bouzkova E; Hrdlicka L; Komarek A; Lukas M
    J Crohns Colitis; 2013 Oct; 7(9):736-43. PubMed ID: 23200919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
    Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
    Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of response to Infliximab in children with luminal Crohn's disease.
    Grover Z; Biron R; Carman N; Lewindon P
    J Crohns Colitis; 2014 Aug; 8(8):739-46. PubMed ID: 24445015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.
    Billiet T; Papamichael K; de Bruyn M; Verstockt B; Cleynen I; Princen F; Singh S; Ferrante M; Van Assche G; Vermeire S
    J Crohns Colitis; 2015 Dec; 9(12):1120-6. PubMed ID: 26351386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
    J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn's disease - an immunohistochemical study.
    Eder P; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Zabel M; Linke K
    J Crohns Colitis; 2013 Oct; 7(9):706-16. PubMed ID: 23021876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab.
    Ogawa K; Matsumoto T; Esaki M; Torisu T; Iida M
    J Crohns Colitis; 2012 Jun; 6(5):529-35. PubMed ID: 22398057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum microRNA levels in patients with Crohn's disease during induction therapy by infliximab.
    Fujioka S; Nakamichi I; Esaki M; Asano K; Matsumoto T; Kitazono T
    J Gastroenterol Hepatol; 2014 Jun; 29(6):1207-14. PubMed ID: 24447044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.